Combination Therapy With DPP-4 Inhibitors and Pioglitazone in Type 2 Diabetes: Theoretical Consideration and Therapeutic Potential

Vascular Health and Risk Management
doi 10.2147/vhrm.s3374
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Qtern: DPP-4 and SGLT2 Inhibitor Combination for Type 2 Diabetes

Prescriber
Pharmacology
2017English

Use of DPP-4 Inhibitors in Type 2 Diabetes: Focus on Sitagliptin

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2010English

Emerging DPP-4 Inhibitors: Focus on Linagliptin for Type 2 Diabetes

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal MedicinePharmacology
2013English

DPP-4/SGLT2 Inhibitor Combined Therapy for Type 2 Diabetes

Prescriber
Pharmacology
2017English

Dipeptidyl Peptidase 4 (Dpp-4) Inhibitors for the Treatment of Type 2 Diabetes Mellitus

Journal of thee Medical Sciences (Berkala Ilmu Kedokteran)
2016English

Systematic Literature Review of DPP-4 Inhibitors in Patients With Type 2 Diabetes Mellitus and Renal Impairment

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2016English

Combination of Empagliflozin and Metformin Therapy: A Consideration of Its Place in Type 2 Diabetes Therapy

Clinical Medicine Insights: Endocrinology and Diabetes
Internal MedicineEndocrinologyMetabolismDiabetes
2018English

Need for Streamlined Use of DPP-4 Inhibitors in the Treatment of Type 2 Diabetes

Cardiovascular Diabetology
Internal MedicineCardiologyEndocrinologyCardiovascular MedicineMetabolismDiabetes
2016English

The Old and the New in the Treatment of Type 2 Diabetes: Focus on the Combination Therapy With Dipeptidyl Peptidase-4 Inhibitors and Metformin

Clinical Medicine Insights: Therapeutics
MedicinePharmacologyPharmaceutical Science
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy